-
Court upholds Lilly's patent for Cymbalta
INDIANAPOLIS — Drug maker Eli Lilly will get at least two more years of patent exclusivity on a drug used to treat depression, anxiety and pain resulting from diabetic neuropathy and fibromyalgia, thanks to a court order issued Wednesday.
The U.S. District Court for the Southern District of Indiana ruled to forbid Wockhardt and other generic drug companies from selling generic versions of Cymbalta (duloxetine hydrochloride) until patent protection expires, which is expected to occur in June 2013.
-
Bayer extends sponsorship agreement with World Federation of Hemophilia
MONTVILLE, N.J. — Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia announced Thursday a three-year extension of Bayer’s sponsorship agreement with the WFH.
The agreement calls for Bayer to serve as the sole sponsor of the WFH’s International Hemophilia Training Centre program and provide support for other activities of the organiztion, such as its website and Congress. The program trains healthcare professionals in developing countries in diagnosis and management of hemophilia and related bleeding disorders.